Xoma | XOMA - Current Assets


Xoma reported $110.71M in Current Assets for its fiscal quarter ending in September of 2025.





Current Assets Change Date
AbbVie USD 33.53B 4.47B Mar/2026
Agenus USD 95.28M 38.15M Mar/2026
Agios Pharmaceuticals USD 834.84M 107.21M Mar/2026
Ardelyx USD 381.87M 447K Mar/2026
aTyr Pharma USD 67.58M 178.23M Mar/2026
BioMarin Pharmaceutical USD 4.61B 651.58M Mar/2026
Celldex Therapeutics USD 459.22M 75.44M Mar/2026
Curis USD 6.92M 7.5M Dec/2025
Eli Lilly USD 54.84B 794M Mar/2026
Emergent BioSolutions USD 679.5M 41.3M Dec/2023
Incyte USD 5.48B 460.36M Mar/2026
MacroGenics USD 182.52M 37.42M Mar/2026
Novartis USD 26.61B 3.85B Mar/2026
Novartis USD 30.46B 2.26B Dec/2025
Pfizer USD 42.82B 76M Mar/2026
Prothena USD 339.2M 24.01M Mar/2026
Regeneron Pharmaceuticals USD 18.21B 187.3M Mar/2026
Xoma USD 110.71M 5.78M Sep/2025